University of Vermont Medical Center Initiates Evaluation of the ECGenius System as CathVision Prepares for U.S. LaunchCOPENHAGEN, Denmark, April 26, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to guide and enhance cardiac ablation therapy through the acquisition of low-noise, high-fidelity electrograms, today announced the completion of patient enrollment in the CathVision ECGenius System clinical evaluation study at the University of Vermont Medical Center.
